Caron A. Jacobson, MD, MMSc

Articles

Looking Ahead to the Future of CAR T Therapy for B-Cell Lymphoma

October 31st 2025

Panelists discuss how CAR T therapy represents the best curative option for relapsed B-cell lymphoma and how community oncologists must prepare for the inevitable expansion of cellular therapies across multiple disease areas.

Considerations for Patients With B-Cell Lymphoma CAR T to Be Treated in the Community Setting

October 24th 2025

Panelists discuss how expanding CAR T to more community sites requires adequate volume, intensive care unit support, and subspecialty backup, while recognizing that not every center should administer this therapy.

Additional Resources Needed in the Community Setting to Manage CAR T in Patients With B-Cell Lymphoma

October 24th 2025

Panelists discuss how community practices need better systems for disseminating CAR T care guidelines to all team members and clearer vaccination schedules for patients post CAR T.

Transitioning Patients Back to the Community Setting After CAR T Therapy for B-Cell Lymphoma

October 17th 2025

Panelists discuss how the timing of community transition depends on ongoing toxicities and patient comfort levels, with continued communication essential for managing lingering effects like cytopenias and autonomic dysfunction.

Discussing the Risk of Secondary Cancers From CAR T Therapy in Patients With B-Cell Lymphoma

October 17th 2025

Panelists discuss how the extremely rare risk of T-cell malignancies after CAR T therapy should be contextualized against the certain mortality risk of untreated refractory lymphoma.

CMV Reactivation Monitoring and the Management of Persistent Cytopenias

October 10th 2025

Panelists discuss how CMV monitoring should be implemented for patients who received extensive corticosteroids and how persistent cytopenias beyond 6 months warrant bone marrow evaluation.

Monitoring for the Late-Phase Toxicities of CAR T for B-Cell Lymphomas

October 10th 2025

Panelists discuss how community oncologists should manage long-term CAR T complications, including hypogammaglobulinemia, cytopenias, and opportunistic infections while maintaining communication with treating centers.

Preventing the Early-Phase CAR T Toxicities for B-Cell Lymphomas

October 3rd 2025

Panelists discuss how preventive strategies like dexamethasone can reduce high-grade toxicities in high-risk patients while prophylactic tocilizumab is avoided due to increased neurotoxicity risk.

Predicting the Early-Phase CAR T Toxicities for B-Cell Lymphomas

October 3rd 2025

Panelists discuss how acute CAR T toxicities follow predictable patterns based on specific products, with cytokine release syndrome typically preceding neurotoxicity and inflammatory markers serving as early indicators.

Removing Barriers and Expanding Access to CAR T Therapy for B-Cell Lymphoma

September 26th 2025

Panelists discuss how the dissolution of REMS requirements and availability of outpatient CAR T therapy have significantly improved access by reducing monitoring restrictions and caregiver requirements.

Communicating the Value of CAR T in the Treatment of B-Cell Lymphoma

September 26th 2025

Panelists discuss how community oncologists can overcome misconceptions about CAR T toxicity by understanding that the therapy has evolved to be safer, with shorter hospital stays and better outcomes.

Sending Patients to Referral Centers for CAR T and Bispecific Antibody Treatment Decisions for B-Cell Lymphoma

September 19th 2025

Panelists discuss how community oncologists should navigate referral processes to academic centers and balance CAR T therapy against other emerging treatments like bispecific antibodies based on curative potential.

Improved Patient Outcomes With CAR T as an Early Line of Treatment

September 19th 2025

Panelists discuss how earlier referrals for CAR T therapy led to better outcomes due to healthier T cells, reduced need for bridging therapy, and improved survival benefits demonstrated in clinical trials.

CAR T Patient Eligibility for B-Cell Lymphoma

September 12th 2025

Panelists discuss how eligibility criteria for CAR T therapy have expanded over time, emphasizing that all patients meeting disease indications should be referred to treatment centers rather than having community oncologists make exclusion decisions.

Discussing CAR T as an Early Treatment Option for B-Cell Lymphoma

September 12th 2025

Panelists discuss how community oncologists should introduce CAR T therapy during the first consultation with lymphoma patients to provide reassurance about available treatment options and establish the full treatment pathway.

Key Takeaways: CAR T in Real-World Clinical Practice

April 23rd 2025

Experts share their closing thoughts and key take-home messages from this discussion.

Overcoming Barriers and Improving CAR T Care in Academic and Community Settings

April 23rd 2025

Experts discuss the challenges and barriers in early referral for chimeric antigen receptor T-cell therapy (CAR T) and how post–CAR T follow-up care is managed between academic and community settings.

CAR T in CLL: Data Highlights and Long-Term Outcomes From ASH 2024

April 16th 2025

Experts discuss recent data updates from the TRANSCEND CLL-004 study on the combination of lisocabtagene maraleucel (liso-cel) and ibrutinib, the potential curative role of chimeric antigen receptor T-cell therapy (CAR T) in relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and the future outlook for CAR T in treating R/R CLL.

Novel Combination Therapies in First-Line CLL: Potential Impact of Treatment Sequencing

April 16th 2025

Experts discuss novel combination therapies in first-line chronic lymphocytic leukemia (CLL) and their potential impact on treatment sequencing and patient outcomes.

Optimizing CAR T for R/R CLL: Timing and Treatment Sequencing Strategies

April 9th 2025

Experts discuss when to consider chimeric antigen receptor T-cell therapy (CAR T) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients and how to sequence CAR T and pirtobrutinib in clinical practice for those who have previously received both covalent Bruton tyrosine kinase (cBTK) inhibitor– and BCL2 inhibitor–containing regimens.